Premium
P3‐367: Model‐based analysis to support strategic decision‐making: A case study from the development of a 5HT6 antagonist for the treatment of Alzheimer's disease
Author(s) -
Rogers James,
Polhamus Dan,
Lockwood Peter,
Brault Yves,
Desmet Anne,
Ito Kaori,
Romero Klaus,
Qiu Ruolun,
Corrigan Brian,
Gillespie William,
Gastonguay Marc
Publication year - 2012
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2012.05.1592
Subject(s) - donepezil , interim analysis , interim , covariate , placebo , psychology , longitudinal study , clinical endpoint , regimen , longitudinal data , medicine , clinical trial , disease , physical medicine and rehabilitation , computer science , econometrics , statistics , data mining , mathematics , dementia , geography , alternative medicine , archaeology , pathology
P3-367 MODEL-BASED ANALYSIS TO SUPPORT STRATEGIC DECISION-MAKING: A CASE STUDY FROM THE DEVELOPMENT OFA 5HT6 ANTAGONIST FOR THE TREATMENT OF ALZHEIMER’S DISEASE James Rogers, Dan Polhamus, Peter Lockwood, Yves Brault, Anne Desmet, Kaori Ito, Klaus Romero, Ruolun Qiu, Brian Corrigan, William Gillespie, Marc Gastonguay, Metrum Research Group, Tariffville, Connecticut, United States; Pfizer, Groton, Connecticut, United States; Pfizer, Paris, Ile-de-France, France; Pfizer, Paris, Ile-de-France, United States; Pfizer Inc., New London, Connecticut, United States; Critical Path Institute, Tucson, Arizona, United States; Pfizer Inc., Groton, Connecticut, United States; Pfizer, New London, Connecticut, United States.